Jump Financial LLC Lowers Position in Church & Dwight Co., Inc. (NYSE:CHD)

Jump Financial LLC lessened its position in Church & Dwight Co., Inc. (NYSE:CHD - Free Report) by 68.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 2,412 shares of the company's stock after selling 5,232 shares during the period. Jump Financial LLC's holdings in Church & Dwight were worth $253,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of CHD. Norges Bank acquired a new stake in Church & Dwight in the 4th quarter valued at $318,532,000. JPMorgan Chase & Co. lifted its stake in shares of Church & Dwight by 19.4% in the fourth quarter. JPMorgan Chase & Co. now owns 7,336,046 shares of the company's stock valued at $768,157,000 after buying an additional 1,190,154 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Church & Dwight during the fourth quarter valued at about $76,565,000. World Investment Advisors LLC bought a new stake in shares of Church & Dwight during the third quarter worth about $58,338,000. Finally, Barclays PLC raised its holdings in shares of Church & Dwight by 63.9% in the 3rd quarter. Barclays PLC now owns 1,106,131 shares of the company's stock worth $115,832,000 after acquiring an additional 431,257 shares during the last quarter. Institutional investors own 86.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on CHD. Truist Financial lifted their price target on Church & Dwight from $110.00 to $115.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Royal Bank of Canada reiterated a "sector perform" rating and set a $105.00 price target on shares of Church & Dwight in a report on Monday, February 3rd. JPMorgan Chase & Co. dropped their price objective on Church & Dwight from $106.00 to $98.00 and set an "underweight" rating on the stock in a research note on Friday, April 11th. Barclays cut their price objective on shares of Church & Dwight from $97.00 to $94.00 and set an "underweight" rating on the stock in a report on Friday, April 11th. Finally, Evercore ISI lowered their target price on shares of Church & Dwight from $106.00 to $102.00 and set an "in-line" rating for the company in a report on Friday. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $112.35.

Insiders Place Their Bets

In other Church & Dwight news, EVP Maynadier Patrick D. De sold 54,510 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $115.98, for a total value of $6,322,069.80. Following the completion of the transaction, the executive vice president now owns 10,497 shares in the company, valued at $1,217,442.06. This trade represents a 83.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Rene Hemsey sold 11,060 shares of Church & Dwight stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $109.98, for a total value of $1,216,378.80. Following the transaction, the executive vice president now directly owns 6,437 shares of the company's stock, valued at $707,941.26. The trade was a 63.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 65,570 shares of company stock worth $7,538,449 over the last quarter. 2.00% of the stock is currently owned by company insiders.

Church & Dwight Stock Performance

Shares of CHD stock traded up $0.08 during trading hours on Friday, hitting $92.46. 899,519 shares of the company were exchanged, compared to its average volume of 1,568,530. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $22.75 billion, a price-to-earnings ratio of 38.95, a P/E/G ratio of 3.32 and a beta of 0.55. The firm has a fifty day simple moving average of $106.21 and a 200 day simple moving average of $105.99. Church & Dwight Co., Inc. has a 52-week low of $91.77 and a 52-week high of $116.46.

Church & Dwight (NYSE:CHD - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $0.02. Church & Dwight had a return on equity of 20.03% and a net margin of 9.58%. The business had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.52 billion. During the same period last year, the business posted $0.96 earnings per share. The business's revenue for the quarter was down 2.4% on a year-over-year basis. Research analysts predict that Church & Dwight Co., Inc. will post 3.7 earnings per share for the current fiscal year.

Church & Dwight Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Thursday, May 15th will be issued a dividend of $0.295 per share. This represents a $1.18 annualized dividend and a yield of 1.28%. The ex-dividend date is Thursday, May 15th. Church & Dwight's dividend payout ratio (DPR) is presently 49.79%.

Church & Dwight Profile

Church & Dwight Co, Inc engages in the development, manufacture, and marketing of household, personal care, and specialty products. It operates through the following segments: Consumer Domestic, Consumer International, Specialty Products Division (SPD), and Corporate. The Consumer Domestic segment offers household products, such as laundry detergents, fabric softener sheets, cat litter, household cleaning products, and personal care products including antiperspirants, oral care products, depilatories, reproductive health products, oral analgesics, nasal saline moisturizers, and dietary supplements.